» Articles » PMID: 9808413

The Complement Regulatory Proteins CD46 and CD59, but Not CD55, Are Highly Expressed by Glandular Epithelium of Human Breast and Colorectal Tumour Tissues

Overview
Journal APMIS
Date 1998 Nov 10
PMID 9808413
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Three of the proteins protecting cells from autologous lysis by complement are: membrane cofactor protein (MCP; CD46), an inhibitor of the membrane attack complex formation (CD59), and decay accelerating factor (DAF; CD55). We have investigated the expression of these proteins in breast and colorectal carcinoma by immunohistochemistry and immunoblotting of breast tissue for CD46. CD46 was consistently and strongly expressed in the epithelial compartment in 26/28 ductal carcinomas of the breast, 9/9 fibroadenomas, and 9/11 cases of control non-neoplastic breast tissue. CD59 showed a similar degree of expression in the fibroadenomas (9/9), but was less strongly expressed in carcinomatous (22/28) and control (5/11) tissues. In marked contrast, no CD55 expression was detected in tissue from 15 ductal carcinomas. Immunoblotting of breast tissue for CD46 showed the same size of the molecule as for lymphocytes. It had however considerably stronger expression in tumour tissue than in non-neoplastic tissue. CD46 and CD59 were either lacking or only weakly expressed in the epithelial component of control colorectal mucosa: 2/15 and 5/15, respectively. In contrast, tissue samples from colorectal adenocarcinomas showed clear staining for both CD59 (10/18) and, more markedly, CD46 (15/18). There was no association between the pattern or intensity of CD46 and CD59 expression and tumour differentiation. As the complement regulatory proteins CD46 and CD59 are also strongly expressed by trophoblast at the feto-maternal tissue interface, these results support the concept that similar mechanisms are employed both by the genetically dissimilar fetus and certain tumours to evade immune attack by their host.

Citing Articles

Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.

Alekseeva O, Hoa L, Vorobyev P, Kochetkov D, Gumennaya Y, Naberezhnaya E Cancers (Basel). 2024; 16(18).

PMID: 39335111 PMC: 11430599. DOI: 10.3390/cancers16183139.


Association of complement components with risk of colorectal cancer: A systematic review and meta-analysis.

Zhu X, Zhang L, Qi S World J Gastrointest Oncol. 2024; 16(5):2168-2180.

PMID: 38764810 PMC: 11099464. DOI: 10.4251/wjgo.v16.i5.2168.


Toward the understanding of DSG2 and CD46 interaction with HAdV-11 fiber, a super-complex analysis.

Effantin G, Hograindleur M, Fenel D, Fender P, Vassal-Stermann E J Virol. 2023; 97(11):e0091023.

PMID: 37921471 PMC: 10688334. DOI: 10.1128/jvi.00910-23.


A Renaissance for Oncolytic Adenoviruses?.

Blanchette P, Teodoro J Viruses. 2023; 15(2).

PMID: 36851572 PMC: 9964350. DOI: 10.3390/v15020358.


High-throughput surface marker screen on primary human breast tissues reveals further cellular heterogeneity.

Virtanen S, Schulte R, Stingl J, Caldas C, Shehata M Breast Cancer Res. 2021; 23(1):66.

PMID: 34120626 PMC: 8201685. DOI: 10.1186/s13058-021-01444-5.